Gleevec (imatinib) Approved for Expanded Use

Share this content:
Gleevec (imatinib) Approved for Expanded Use
Gleevec (imatinib) Approved for Expanded Use

(ChemotherapyAdvisor) – The U.S. Food and Drug Administration has approved an update to the Gleevec (imatinib mesylate) tablets label to recommend 36 months of treatment after surgery in adult patients with KIT (CD117)-positive gastrointestinal stromal tumors (GIST) who are at risk of recurrence.

The updated label will reflect data from an international, multicenter, open-label Phase 3 clinical trial of imatinib that demonstrated a 54% reduction in risk of recurrence for those treated with imatinib for 36 vs. 12 months (P<0.0001). At 60 months, 92% of patients who received 36 months of imatinib were alive vs. 82% who received 12 months of imatinib.

“Although originally approved in the metastatic disease setting, this subsequent trial has demonstrated that longer use of Gleevec can prolong patient's lives in earlier disease settings,” said Richard Pazdur, MD, of the FDA's Center for Drug Evaluation and Research.

The most common adverse events observed in patients receiving imatinib include edema, nausea, vomiting, muscle cramps, bone or muscle pain, diarrhea, rash, fatigue, and abdominal pain.

In 2008, imatinib received accelerated approval for this use. Imatinib is marketed by Novartis Pharmaceuticals Corp.

ASCO 2011 Abstract

FDA Press Release

Novartis Press Release

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs